Business Wire

NOMIOS-GROUP

2.3.2023 06:33:06 CET | Business Wire | Press release

Share
Nomios Group Expands in Southern Europe with the Leading Italian Cybersecurity Expert Aditinet

Nomios Group, a leading European provider of cybersecurity services and solutions, announced today that it has completed the acquisition of a majority stake in Aditinet, a prominent cybersecurity company in the Italian market. The acquisition strengthens Nomios’ European position as one of the leading cybersecurity service companies.

“This acquisition marks an important step in Nomios’ continued growth and success, and we see many benefits in terms of a shared vendor portfolio, customer relationship, and service offerings. Not only does the acquisition of Aditinet provide the Nomios Group with a significant expertise and strong customer base in Italy, but it also allows us to add new services such as ethical hacking to our portfolio” explained Sébastien Kher, CEO of Nomios Group.

With the addition of Aditinet, the Nomios Group annual revenue grows to EUR 400M, and its consolidated headcount grows to over 600 FTEs throughout its seven European markets. The current CEO and Founder (Paolo Marsella) and CFO (Alberto Mez) will remain minority shareholders and will continue to manage the company and will lead the integration within the Nomios Group.

“Becoming part of Nomios is the ideal next step in realising Aditinet’s vision of making IT and the cloud the most secure environment for our customers and in further consolidating our relationships with critical vendors” said Paolo Marsella, CEO of Aditinet. “Nomios will provide European scale and expertise to further accelerate our growth in the Italian market. We look forward to immediately take advantage of Nomios’ famous SOC capabilities to help monitor our customer’s security perimeters and rely on their many references in SASE. We see a lot of talks about these technologies in the market, and our new Nomios colleagues have already proven that they can deliver in both respects”.

About Nomios Group

Nomios is a leading European provider of cybersecurity and secure networking solutions and services and has a broad customer base in highly diversified sectors. In 19 years, Nomios has grown into an organisation with more than 20 offices in seven European countries and has continuously expanded its own professional services, managed services, support and SOC offering. Nomios has the most experienced, loyal and highly certified pool of engineers in its industry, as recognised by many third-party studies, and has strategic partnerships with leading technology providers, including Palo Alto Networks, Juniper Networks, Cisco, Fortinet, F5, and others. In January 2019, funds advised by IK Partners, a leading Pan-European private equity firm, acquired a majority stake in Nomios Group.

About Aditinet

Founded in 2004, Aditinet is an Italian system integration and professional services company specialising in cybersecurity. With an annual revenue of EUR 40 million, Aditinet is among the most recognised players in the Italian cybersecurity industry with best-in- class certifications with Palo Alto Networks (Diamond) and F5 (Platinum) among other highly ranked vendor partnerships. Aditinet has two main offices in Italy, namely in Rome and Milan. Aditinet serves over 150 customers, which include several Italian national banks, utility providers, universities, manufacturing companies and ministries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228006051/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release

Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release

Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly

SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release

The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter

Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release

Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant

Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye